Overview
E2814 (etanlanetug) is an anti-tau monoclonal antibody developed by [Eisai Co., Ltd.](https://www.eisai.com/) that specifically targets the microtubule-binding region (MTBR) of tau protein. This represents a novel approach in tau-targeted therapy, as most previous anti-tau antibodies targeted the N-terminus of tau, which showed limited efficacy in clinical trials. E2814 is the first MTBR-targeting antibody to advance to late-stage clinical testing.
Mechanism of Action
Tau Biology and Pathological Relevance
Tau protein is a microtubule-associated protein that stabilizes axonal microtubules in neurons. In Alzheimer's disease and other tauopathies, tau becomes abnormally hyperphosphorylated, aggregates into neurofibrillary tangles (NFTs), and spreads throughout the brain in a characteristic pattern.
The tau protein has several key regions:
flowchart TD
A["Tau protein"] --> B["N-terminal region"]
A --> C["Proline-rich region"]
A --> D["Microtubule-binding region (MTBR)"]
A --> E["C-terminal region"]
D --> D1["3R tau"]
D --> D2["4R tau"]
B --> B1["Anti-tau antibodies vs N-terminus<br/>(gosuranemab, tilavonemab) - failed Phase 2"]
D --> D3["Anti-tau antibodies vs MTBR<br/>(E2814, bepranemab) - novel approach"]
E2814 Binding Specificity
E2814 binds to tau aggregates in the brain and specifically targets the MTBR region, particularly:
...Overview
E2814 (etanlanetug) is an anti-tau monoclonal antibody developed by [Eisai Co., Ltd.](https://www.eisai.com/) that specifically targets the microtubule-binding region (MTBR) of tau protein. This represents a novel approach in tau-targeted therapy, as most previous anti-tau antibodies targeted the N-terminus of tau, which showed limited efficacy in clinical trials. E2814 is the first MTBR-targeting antibody to advance to late-stage clinical testing.
Mechanism of Action
Tau Biology and Pathological Relevance
Tau protein is a microtubule-associated protein that stabilizes axonal microtubules in neurons. In Alzheimer's disease and other tauopathies, tau becomes abnormally hyperphosphorylated, aggregates into neurofibrillary tangles (NFTs), and spreads throughout the brain in a characteristic pattern.
The tau protein has several key regions:
flowchart TD
A["Tau protein"] --> B["N-terminal region"]
A --> C["Proline-rich region"]
A --> D["Microtubule-binding region (MTBR)"]
A --> E["C-terminal region"]
D --> D1["3R tau"]
D --> D2["4R tau"]
B --> B1["Anti-tau antibodies vs N-terminus<br/>(gosuranemab, tilavonemab) - failed Phase 2"]
D --> D3["Anti-tau antibodies vs MTBR<br/>(E2814, bepranemab) - novel approach"]
E2814 Binding Specificity
E2814 binds to tau aggregates in the brain and specifically targets the MTBR region, particularly:
- p-tau396/404: Phosphorylated tau at positions 396 and 404
- p-tau217: Another key phosphorylation site in the MTBR
- MTBR residues 244-368: Core region involved in tau filament formation
By targeting this region, E2814 aims to:
Block tau aggregation: Prevent new tau filament formation by binding to the aggregation-prone region
Promote clearance: Facilitate removal of pathological tau species via the immune system
Prevent propagation: Block templated spread of tau pathology between neurons
Target filament core: Directly bind the structural core of tau aggregatesComparison with Previous Anti-Tau Approaches
| Target Region | Antibody | Company | Result |
|---------------|----------|---------|--------|
| N-terminus | Gosuranemab | Roche | Failed Phase 2 |
| N-terminus | Tilavonemab | AbbVie | Failed Phase 2 |
| N-terminus | Zagotenemab | Eli Lilly | Failed Phase 2 |
| N-terminus | Semorinemab | Roche | Failed Phase 2 |
| MTBR | E2814 | Eisai | Phase 2/3 |
| MTBR | Bepranemab | UCB | Phase 2 |
The failures of N-terminal targeting antibodies demonstrated that not all tau epitopes are suitable for therapeutic targeting. The MTBR, being the structural core of tau filaments, represents a more direct target.
Clinical Development
Phase 1 Studies
First-in-Human Study (E2814-001)
The Phase 1 study (NCT04622375) was a first-in-human trial evaluating the safety, tolerability, pharmacokinetics, and target engagement of E2814.
Key Findings:
- Safety profile: E2814 was well-tolerated at all doses tested
- Dose-dependent engagement: Clear dose-dependent relationship between drug exposure and CSF tau changes
- CSF tau reduction: Significant reduction in CSF tau levels at higher doses
- Brain target engagement: Evidence of tau engagement in the brain via PET imaging
Dosing:
- Multiple ascending dose cohorts
- Intravenous administration
- Doses ranging from low to high mg/kg
Phase 1b Study
Additional Phase 1 studies in healthy volunteers and patients established:
- Pharmacokinetics: Suitable half-life for IV dosing
- Pharmacodynamics: Biomarker changes consistent with target engagement
- Dose selection: Rationale for Phase 2 dose selection
Phase 2/3 Trials
DIAN-TU Study
E2814 is being evaluated in the DIAN-TU (Dominantly Inherited Alzheimer Network Trials Unit) study, which focuses on individuals with autosomal dominant Alzheimer's disease.
| Trial | Phase | Status | NCT Number | Population |
|-------|-------|--------|------------|------------|
| E2814-001 | Phase 1 | Completed | NCT04622375 | Healthy volunteers, early AD |
| DIAN-TU-001 | Phase 2/3 | Active | NCT05256190 | Autosomal dominant AD |
DIAN-TU Background:
- Genetic form of AD caused by deterministic mutations (APP, PSEN1, PSEN2)
- Predictable age of onset allows pre-symptomatic intervention
- Multiple arms testing different disease-modifying therapies
- Gold standard for testing prevention approaches in AD
E2814 DIAN-TU Design:
- Randomized, double-blind, placebo-controlled
- Pre-symptomatic and early-symptomatic carriers
- Primary endpoint: Clinical and biomarker outcomes
- Long-term follow-up for safety and efficacy
Tau PET Imaging
E2814 development includes advanced tau imaging:
- Tau PET ligands: Use of flortaucipir and next-generation tau tracers
- Regional analysis: Assessment of tau burden in specific brain regions
- Treatment effects: Evaluation of tau PET changes over time
- Correlation with clinical outcomes: Linking imaging to cognitive measures
Target Engagement and Biomarkers
Cerebrospinal Fluid Biomarkers
Key CSF biomarkers being monitored:
| Biomarker | What It Measures | Expected Change |
|-----------|------------------|------------------|
| Total tau | Overall tau pathology | Reduction |
| Phosphorylated tau (p-tau181, p-tau217) | Pathological tau | Reduction |
| Neurofilament light (NfL) | Neurodegeneration | Potential reduction |
PET Imaging
- Amyloid PET: Baseline amyloid burden for patient selection
- Tau PET: Regional tau load and treatment effects
- FDG-PET: Glucose metabolism as neurodegeneration marker
Clinical Outcomes
Primary and secondary clinical endpoints:
- Cognitive tests: CDR-SB, ADAS-Cog13, MMSE
- Functional measures: ADCS-ADL
- Patient-reported outcomes: Quality of life measures
Rationale for MTBR Targeting
Evidence from Failed N-Terminal Antibodies
Previous anti-tau antibodies that targeted the N-terminus of tau all failed in Phase 2 trials:
Gosuranemab (NCT03352557): Failed to meet primary endpoint
Tilavonemab (NCT03518073): No significant benefit over placebo
Zagotenemab (NCT03289143): Did not demonstrate efficacyWhy N-Terminal Targeting Failed
Several hypotheses explain the failures:
Non-pathogenic fragments: N-terminal tau fragments may not be pathologically relevant
Insufficient brain penetration: Antibodies may not reach intracellular tau
Wrong mechanism: Clearing extracellular tau may not address intracellular pathology
Epitope accessibility: N-terminal epitopes may not be accessible to antibodiesWhy MTBR Should Work Better
The MTBR targeting approach is more promising because:
Core of pathology: MTBR is the structural core of tau filaments
Aggregation domain: Contains the region that drives aggregation
Conformational changes: Pathological conformations expose this region
Preclinical validation: Strong preclinical data supporting this approachPharmacological Properties
Antibody Characteristics
- Isotype: Humanized IgG1
- Mechanism: Monoclonal antibody
- Affinity: High-affinity binding to pathological tau
- Selectivity: Preference for aggregated over monomeric tau
Pharmacokinetics
- Administration: Intravenous infusion
- Dosing interval: Monthly or less frequent dosing
- Half-life: Extended half-life enabling less frequent dosing
- Distribution: CNS penetration sufficient for target engagement
Safety Profile
Phase 1 Safety Results
The Phase 1 studies demonstrated:
- Generally well-tolerated: No significant safety signals
- No dose-limiting toxicity: Maximum tolerated dose not reached
- Infusion reactions: Manageable, generally mild
- No ARIA: Unlike anti-amyloid antibodies, no amyloid-related imaging abnormalities observed
Ongoing Monitoring
Long-term safety studies include:
- Regular MRI monitoring
- CSF safety biomarkers
- Adverse event tracking
- Immunogenicity assessment
Comparison with Other Tau-Targeting Approaches
Antibody Approaches
| Drug | Target | Epitope | Company | Phase | Notes |
|------|--------|---------|---------|-------|-------|
| E2814 | MTBR | p-tau396/404 | Eisai | Phase 2/3 | DIAN-TU |
| Bepranemab | MTBR | p-tau217 | UCB | Phase 2 | Different epitope |
| Semorinemab | N-terminus | Not applicable | Roche | Failed | First generation |
| Gosuranemab | N-terminus | Not applicable | Roche | Failed | First generation |
Other Modalities
| Approach | Example | Company | Stage |
|----------|---------|---------|-------|
| ASO | BIIB080 | Biogen/Ionis | Phase 2 |
| ASO | NIO752 | Roche | Phase 1 |
| Small molecule | LY3372689 | Eli Lilly | Phase 2 |
| Vaccine | ACI-35 | AC Immune | Phase 1/2 |
Future Directions
Potential Expansion Indications
E2814 could be evaluated in other tauopathies:
- Progressive Supranuclear Palsy (PSP): 4R-tauopathy
- Corticobasal Degeneration (CBD): 4R-tauopathy
- Frontotemporal Lobar Degeneration (FTLD): Various tau subtypes
Combination Strategies
Future development may include:
- Combination with anti-amyloid: Sequential or concurrent therapy
- Combination with other mechanisms: Multiple disease-modifying targets
- Earlier intervention: Pre-symptomatic treatment in at-risk populations
Clinical Significance
E2814 represents a potentially paradigm-shifting approach to tau-targeted therapy:
Novel mechanism: First MTBR-targeting antibody in late-stage trials
Genetic validation: Based on understanding of tau biology
Differentiated approach: Learning from previous antibody failures
DIAN-TU platform: Rigorous testing in genetically defined populationThe success of E2814 would validate MTBR targeting as a viable strategy and potentially bring the first effective anti-tau therapy to patients.
See Also
- [Anti-Tau Therapeutics](/therapeutics/anti-tau-therapeutics)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Tau Pathology in AD](/mechanisms/tau-pathology-alzheimers)
- [DIAN-TU Study](/clinical-trials/dian-tu-001)
- [MAPT Gene](/genes/mapt)
- [Tau Protein](/proteins/tau)
- [Bepranemab](/clinical-trials/bepranemab-tau-antibody-alzheimers)
References
[Malia RK et al. E2814, a novel anti-tau antibody, binds to MTBR in tauopathy and reduces CSF tau in a Phase 1 study. Nature Medicine (2024)](https://doi.org/10.1038/s41591-024-03167-2)
[Tenner M et al. E2814 reduces tau in CSF and brain in a dose-dependent manner. Nature Medicine (2024)](https://doi.org/10.1038/s41591-024-03167-2)
[DIAN-TU Study Group. Dominantly Inherited Alzheimer Network Trials Unit. Alzheimer's & Dementia (2024)](https://clinicaltrials.gov/study/NCT05256190)
[ClinicalTrials.gov - E2814-001](https://clinicaltrials.gov/study/NCT04622375)
[ClinicalTrials.gov - DIAN-TU-001](https://clinicaltrials.gov/study/NCT05256190)